These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-000363-28 DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS 2009-09-14 due-trials
Reported results Terminated 2007-001961-14 A pilot study of the treatment of facial nodular and nodulocystic basal cell carcinoma with double curettage and cautery followed by application of imiquimod to the base. 2008-05-26 due-trials
Reported results 2008-002169-30 A randomised placebo-controlled trial of metformin on progression of carotid atherosclerosis in non-diabetic patients with cardiovascular disease treated with conventional risk reducing agents 2012-06-01 due-trials
Reported results 2009-011268-13 Optimal management of rheumatoid arthritis patients who require biologic therapy (ORBIT study) 2015-02-11 due-trials
Reported results 2009-011542-25 CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cerv... 2015-04-30 due-trials
Exempt, with results 2010-021447-41 SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group 2017-12-31 not-yet-due
Reported results 2010-024541-67 Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis – pilot phase 2013-12-10 due-trials
Reported results 2011-000300-18 REducing with MetfOrmin Vascular Adverse Lesions in T1DM Vermindering van vaatschade met metformine in type 1 diabetes 2017-02-17 due-trials
Reported results 2011-000501-52 PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms 2020-04-30 due-trials
Exempt, with results Terminated 2011-000642-37 A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX) 2015-01-12 not-yet-due
Reported results 2011-001564-21 Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study) 2014-09-14 due-trials
Reported results 2011-001841-34 A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium. 2015-09-01 due-trials
Reported results 2011-004554-26 Multi-modal effects of Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism; a randomised placebo-controlled Trial (TRUST) 2016-11-18 due-trials
Reported results 2012-002287-26 Comparison of the caries-protective effect of fluoride varnish (Duraphat®) with treatment as usual in nursery school attenders receiving preventive oral health support through the Childsmile Programme... 2017-08-31 due-trials
Reported results Terminated 2013-000228-33 Inhibition of complement activation (eculizumab®) in Guillain-Barré Syndrome study 2016-08-10 due-trials
Other 2013-001627-39 A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer (GOG-0281) not-yet-due
Exempt, with results 2013-002014-13 A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously received ... 2019-12-09 not-yet-due
Ongoing 2013-003047-29 BALLAD - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. BALLAD- undersøgelse af adjuverende kemoterapi efter operation for adenocarcinom i tolvf... not-yet-due
Other 2013-004235-77 Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST). not-yet-due
Exempt 2014-001216-19 Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose esca... not-yet-due
Other 2014-004419-35 Inhibition of Co-Stimulation in Rheumatoid Arthritis not-yet-due
Other 2014-005221-12 OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer not-yet-due
Other 2015-003249-25 An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer. not-yet-due
Reported results 2015-003720-32 Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer 2019-08-01 due-trials
Exempt 2015-003928-31 A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies not-yet-due
Other 2016-002075-10 Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2 not-yet-due
Other 2016-003719-37 StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus (or prediabetes) and Heart Failure (SUGAR-DM-HF) not-yet-due
Other 2017-003232-36 Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial with GOLD Imaging Theranostic (POST-IT) not-yet-due
Other 2017-003460-13 The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised... not-yet-due
Other 2017-004780-13 An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and ... not-yet-due
Other 2018-001843-29 TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia not-yet-due
Other 2018-003662-14 Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, randomi... not-yet-due
Other 2018-003971-37 PRIMUS 004: A multi-arm non-comparative signal seeking phase II platform trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer not-yet-due
Other 2018-004120-11 Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin not-yet-due
Other 2018-004393-10 A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina not-yet-due
Other 2019-001471-36 Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens in R... not-yet-due
Other 2020-001904-41 Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients not-yet-due
Other 2020-004832-48 DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controlled ... not-yet-due